JACKSONVILLE, Fla., Dec. 12, 2017 /PRNewswire/
-- TapImmune Inc. (NASDAQ: TPIV), a leading
clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that the first
patient has been enrolled in a Phase 2 randomized, multi-center, double-blinded, placebo-controlled clinical trial of TapImmune's
novel therapeutic vaccine candidate TPIV200. The 280-patient trial, sponsored by Mayo Clinic, received $13.3 million in grant funding from the U.S. Department of Defense (DoD) to evaluate the prevention of cancer
recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and
radiotherapy/chemotherapy.
TPIV200 is a novel, multi-epitope, peptide-based cancer vaccine that has been shown to induce a robust and long-lasting
"memory" T-cell immune response directed against folate receptor alpha (FRa), a molecule that is overexpressed on the surface of
the vast majority of TNBC cancer cells and is associated with cancer recurrence. As an off-the-shelf vaccine consisting of
several carefully chosen FRa peptides, TPIV200 is uniquely able to stimulate both T "helper" cells and T "killer" cells to target
tumor cells and is expected to cover greater than 85% of human genotypes worldwide.
"We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical
safety and efficacy insight for TPIV200 under this grant," said TapImmune President and CEO Peter
Hoang. "We believe TPIV200 and our other vaccine candidates have an important role to play within the current
immuno-oncology ecosystem by potentially bridging a critical gap not currently addressed by other immunotherapies, which have
shown promise in only a small number of patients. Unlike current approaches, TapImmune's vaccines are designed to produce
broad-based, durable T-cell responses in the vast majority of patients, which we believe are essential for improving clinical
outcomes and ensuring potential regulatory and commercial success. We look forward to providing updates appropriately as this
exciting Phase 2 study continues to enroll patients."
TapImmune and its clinical partners are evaluating TPIV200 in multiple ongoing Phase 2 trials for treating ovarian and breast
cancer, including a randomized dosing trial in TNBC that recently completed patient enrollment. The four-arm trial is designed to
help determine the optimal TPIV200 vaccine dose and regimen to maximize patients' anti-tumor immune responses. Interim
immunogenicity results from this ongoing study are anticipated in the first half of 2018.
Keith L. Knutson. Ph.D., Professor of Immunology in the Department of Immunology, and
Edith A. Perez, M.D., Professor of Medicine in the Division of Hematology and Oncology, both at
Mayo Clinic's Florida campus in Jacksonville, Florida, are the
recipients of the U.S. Department of Defense grant and are leading the Phase 2 trial.
Mayo Clinic and Dr. Knutson have a financial interest in TapImmune for the triple negative breast cancer treatment.
About the Phase 2 Trial
The Phase 2, randomized, multi-center, blinded, controlled trial will enroll 280 women with Stage Ib-IV
triple-negative breast cancer who have completed initial surgery and radiotherapy/chemotherapy, prior to any disease recurrence.
The two-arm trial is designed to compare vaccination with TPIV200 plus an adjuvant (GM-CSF) with a control group that gets GM-CSF
alone. Patients will receive six monthly injections of their assigned treatment regimen for the first six months, followed by
booster doses every six months. In addition to safety monitoring, the primary efficacy endpoint is disease-free survival of
TPIV200-vaccinated patients compared to that of control patients. This study is fully funded by a $13.3
million grant from U.S. Department of Defense.
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase
1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The
company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs)
designed to comprehensively stimulate a patient's killer T-cells and helper T-cells, and to restore or further augment antigen
presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell
vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's
technologies may be used as stand-alone medications or in combination with other treatment modalities.
For additional information, please visit: https://tapimmune.com/
To receive future press releases via email, please visit:
https://tapimmune.com/investors/email-alerts/
Follow us on Twitter @Tapimmune_Inc, or follow
us on Facebook.
For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act
of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance,
and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other
matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and
other factors which could cause actual results to differ materially from those stored in such statements. Such risks,
uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain
regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to
successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q
and other SEC filings which are available through EDGAR at www.sec.gov. The
Company assumes no obligation to update the forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-announces-enrollment-of-first-patient-in-phase-2-clinical-trial-for-treating-triple-negative-breast-cancer-funded-by-us-department-of-defense-300569697.html
SOURCE TapImmune Inc.